Laura Trescott, Joshua Holcomb, Nicholas Spellmon, Cathy Mcleod, Leala Aljehane, Fei Sun, Chunying Li and Zhe Yang Pages 937 - 944 ( 8 )
Cystic Fibrosis (CF) is a serious genetic condition caused by CF transmembrane conductance regulator (CFTR) mutation. CF patients have shortened lifespan due to airway obstruction, infection, and end-stage lung failure. However, recent development in CF therapy suggests a brighter future for CF patients. Targeting specific CFTR mutations aims to potentiate the channel gating activity of impaired CFTR and restore protein trafficking to the plasma membrane. Gene therapy introduces correct CFTR gene into the affected airway epithelium leading to the functional expression of CFTR in CF patients. This review will sum up the current status in CF-cause targeting therapy.
CFTR, chloride transporter, corrector, cystic fibrosis, gene therapy, potentiator.
Department of Biochemistry and Molecular Biology, Wayne State University School of Medicine, 540 East Canfield Street, Detroit, Michigan 48201, USA.